The background, discovery and clinical development of BCR-ABL inhibitors

G.K. Lambert, A.-K. Duhme-Klair, T. Morgan, M.K. Ramjee

Research output: Contribution to journalArticlepeer-review

Abstract

The story of the inhibition of BCR-ABL as a treatment for chronic myelogenous leukaemia serves to illustrate key aspects of the kinase drug discovery and development process. Firstly, elucidation of the disease mechanism enabled identification of the molecular target(s) which catalysed pharmaceutical research and resulted in Gleevec
Original languageEnglish
Pages (from-to)992-999
Number of pages8
JournalDrug discovery today
Volume18
Issue number19-20
DOIs
Publication statusPublished - Oct 2013

Bibliographical note

©2013 Elsevier Ltd. All rights reserved.

Cite this